All In Biotech

Free tool

FAERS Monitor: Cotempla Xr-Odt

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205489 or its brand name (Cotempla Xr-Odt, Methylphenidate). Reports on generic versions are filed under their own applications.

Reports

15,349

Serious

10,239

67% of reports

Hospitalization

3,634

Death reported

1,114

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,503
  • off label use921
  • fatigue782
  • nausea731
  • anxiety727
  • toxicity to various agents688
  • headache680
  • depression578
  • insomnia511
  • somnolence503
  • condition aggravated497
  • dizziness488
  • vomiting462
  • product substitution issue434
  • drug abuse415

Reports by year received

View as table
YearReports
200410
200526
200612
20076
20085
200919
2010165
2011233
2012302
2013425
2014423
2015749
20161,521
20171,106
20181,060
20191,082
2020928
2021870
20221,094
20231,347
20241,384
20251,422
20261,160

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,810 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product substitution issueSignal43410.49.53,660
drug abuseSignal4156.96.22,070
toxicity to various agentsSignal6885.65.22,612
anxietySignal7273.53.31,315
depressionSignal5783.53.21,031
somnolenceSignal5033.43.1869
insomniaSignal5112.62.4521
condition aggravatedSignal4972.22.1345
drug ineffective1,5031.61.5325
headache6801.51.4111
off label use9211.41.4129
fatigue7821.41.383
vomiting4621.31.242
dizziness4881.31.243
nausea7311.31.242

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.